Most Intensive Ivermectin Use Had 74 Percent Reduction in Excess Deaths in Peru: New Study theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress
- In SELECT-PsA 2, 29 percent of bDMARD-IR patients treated with continuous RINVOQ (upadacitinib, 15 mg, once daily) achieved minimal disease activity at 56 weeks, which was consistent with improvements from baseline seen at week 24[1],[2]
- The safety results of RINVOQ 15 mg were consistent with previously reported results in rheumatoid arthritis, with no new significant safety risks identified[1],[3]
- Full results to be presented at the EULAR 2021 Virtual Congress
- RINVOQ is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[2]
ABBVie today announced results of an analysis from the Phase 3 SELECT-PsA 2 clinical trial, showing that continuous treatment with RINVOQ ® resulted in sustained improvements in disease activity for more than one year among patients with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs . 1 At week 56, 29 percent of patients treated with .